Oct 21, 2026 7:05am EDT Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
Sep 29, 2026 7:05am EDT Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Sep 01, 2026 7:05am EDT Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Aug 12, 2026 7:19am EDT Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Jun 30, 2026 7:05am EDT Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
May 12, 2026 7:05am EDT Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Apr 09, 2026 7:05am EDT Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Mar 30, 2026 7:05am EDT Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Feb 04, 2026 7:05am EST Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
